1 / 23

PD-1 & PDL-1 Inhibitors Market - Analysis and Forecast to 2032 | BIS Research

This report will help companies involved in research and development of PD-1/PDL-1 inhibitors to understand the opportunity as well as competition in the segment as well it help venture capital investment firms to make informed decisions on their investment in PD-1/PDL-1 inhibitor therapeutics segment.

bisreports
Download Presentation

PD-1 & PDL-1 Inhibitors Market - Analysis and Forecast to 2032 | BIS Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. res PD-1/PDL-1 Inhibitor Market - A Global and Regional Analysis Table of Content GLOBAL PD-1/PDL-1 INHIBITOR MARKET Focus on Epidemiology, Product, and Region Analysis and Forecast: 2022-2032 August 2022 1 All rights reserved at BIS Research Inc.

  2. BIS Research is a leading market intelligence and technology research company. BIS Research publishes in- depth market intelligence reports focusing on the market estimations, technology analysis, emerging high- growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. GLOBAL PD-1/PDL-1 INHIBITOR MARKET Copyright © 2022 BIS Research Inc. All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third party. 2 All rights reserved at BIS Research Inc.

  3. Table of Content Executive Summary ........................................................................ 24 1.Market Definition ...................................................................... 27 Inclusion and Exclusion Criteria .................................................................... 27 2.Research Scope ....................................................................... 28 1.1 2.1 Target audience ............................................................................................... 29 Key questions answered in the report ........................................................... 29 3.Research Methodology ............................................................. 31 2.2 3.1 Global PD-1/PDL-1 Inhibitor Market: Research Methodology ...................... 31 3.2 Primary Data Sources ..................................................................................... 32 3.3 Secondary Data Sources ................................................................................ 32 3.4 Target Patient Pool Estimation Model ........................................................... 33 Criteria for Company Profiling ........................................................................ 34 4.Markets .................................................................................... 35 3.5 4.1 Market Overview .............................................................................................. 36 4.2 PD-1/PDL-1 Inhibitors: Overview .................................................................... 36 4.2.1PD-1/PDL-1 Inhibitors and their role in Cancer immunotherapy ............. 36 4.2.2Historic Development of PD-1/PDL-1 Inhibitors........................................ 36 4.2.3Mechanism of Action of PD-1/PDL-1 Inhibitors ........................................ 37 4.2.4Market Landscape ....................................................................................... 39 4.2.4.1 Approved PD-1/PDL-1 Inhibitors ...................................................................... 39 GLOBAL PD-1/PDL-1 INHIBITOR MARKET 4.2.4.2 Competitive Landscape .................................................................................... 47 4.2.4.2.1Strategic Activities .................................................................................................... 47 4.2.4.2.2Regional Distribution of Companies......................................................................... 48 4.2.5Market Dynamics ......................................................................................... 52 4.2.5.1 Market Drivers .................................................................................................. 52 4.2.5.1.1Increased Use of PD-1/PDL-1 Inhibitors in Multiple Sub-set of Cancer Indications ............................................................................................................... 52 4.2.5.1.2Increase in PD-1/PDL-1 Inhibitor Based Combination Regimens ........................... 53 4.2.5.2 Market Restraints ............................................................................................. 55 3 All rights reserved at BIS Research Inc.

  4. 4.2.5.2.1Immune-related Adverse Events Associated With PD-1/PDL-1 Inhibitor Treatment are a Cause of Concern......................................................................... 55 4.2.5.2.2Treatment Specific Biomarkers Assays Pose Hinderance to Smooth Adoption of PD-1/PDL-1 Inhibitor Treatment.......................................................................... 56 4.2.5.3 Opportunities .................................................................................................... 56 4.2.5.3.1Promising Therapeutic Outcomes Generating Positive Market Sentiments ............ 56 4.2.5.3.2Demand for Safer and Convenient Formulation ...................................................... 56 5.Indications ............................................................................... 57 5.1 Indications ........................................................................................................ 58 5.1.1Non-Small Cell Lung Cancer (NSCLC) ....................................................... 58 5.1.1.1 Non-Small Cell Lung Cancer (NSCLC): Disease Overview .............................. 58 5.1.1.2 Non-Small Cell Lung Cancer (NSCLC): Disease Pathophysiology ................... 58 5.1.1.3 Non-Small Cell Lung Cancer (NSCLC): Treatment ........................................... 59 5.1.2Melanoma ..................................................................................................... 61 5.1.2.1 Melanoma: Disease Overview .......................................................................... 61 5.1.2.2 Melanoma: Disease Pathophysiology ............................................................... 61 5.1.2.3 Melanoma: Treatment ...................................................................................... 62 5.1.3Hepatocellular Carcinoma (HCC) ............................................................... 65 5.1.3.1 Hepatocellular Carcinoma (HCC): Disease Overview ....................................... 65 5.1.3.2 Hepatocellular Carcinoma (HCC): Disease Pathophysiology ............................ 65 5.1.3.3 Hepatocellular Carcinoma (HCC): Treatment ................................................... 66 5.1.4Colorectal Cancer (CRC) ............................................................................. 69 GLOBAL PD-1/PDL-1 INHIBITOR MARKET 5.1.4.1 Colorectal Cancer (CRC): Disease Overview ................................................... 69 5.1.4.2 Colorectal Cancer (CRC): Disease Pathophysiology ........................................ 70 5.1.4.3 Colorectal Cancer (CRC): Treatment ............................................................... 71 5.1.5Breast Cancer .............................................................................................. 74 5.1.5.1 Breast Cancer: Disease Overview .................................................................... 74 5.1.5.2 Breast Cancer: Pathophysiology ...................................................................... 74 5.1.5.3 Breast Cancer: Treatment ................................................................................ 75 5.1.6Urothelial Carcinoma .................................................................................. 77 4 All rights reserved at BIS Research Inc.

  5. 5.1.6.1 Urothelial Carcinoma: Disease Overview ......................................................... 77 5.1.6.2 Urothelial Carcinoma: Pathophysiology ............................................................ 78 5.1.6.3 Urothelial Carcinoma: Treatment ...................................................................... 78 6.Products .................................................................................. 82 6.1 Global PD-1/PDL-1 Inhibitor Pipeline Analysis (by Phase) .......................... 83 6.1.1By Development Phase ............................................................................... 83 6.1.2By Drug Class .............................................................................................. 83 6.1.3By Route of Administration (RoA) ............................................................. 84 6.1.4By Monotherapy/Combination Therapy Type ........................................... 85 6.1.5By Target ...................................................................................................... 98 7.Region ..................................................................................... 99 7.1 North America ................................................................................................ 101 7.1.1Melanoma ................................................................................................... 102 7.1.1.1 Melanoma: Epidemiology ............................................................................... 102 7.1.2Breast Cancer ............................................................................................ 103 7.1.2.1 Breast Cancer: Epidemiology ......................................................................... 103 7.1.3Colorectal Cancer (CRC) ........................................................................... 104 7.1.3.1 Colorectal Cancer (CRC): Epidemiology ........................................................ 104 7.1.4Non-Small Cell Lung Cancer (NSCLC) ..................................................... 105 7.1.4.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology .................................... 105 7.1.5Hepatocellular Carcinoma (HCC) ............................................................. 106 7.1.5.1 Hepatocellular Carcinoma (HCC): Epidemiology ............................................ 106 GLOBAL PD-1/PDL-1 INHIBITOR MARKET 7.1.6Urothelial Carcinoma ................................................................................ 107 7.1.6.1 Urothelial Carcinoma: Epidemiology ............................................................... 107 7.2 U.K. ................................................................................................................. 109 7.2.1Non-Small Cell Lung Cancer (NSCLC) ..................................................... 110 7.2.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology .................................... 110 7.2.2Melanoma ................................................................................................... 111 7.2.2.1 Melanoma: Epidemiology ............................................................................... 111 7.2.3Hepatocellular Carcinoma (HCC) ............................................................. 112 5 All rights reserved at BIS Research Inc.

  6. 7.2.3.1 Hepatocellular Carcinoma (HCC): Epidemiology ............................................ 112 7.2.4Colorectal Cancer (CRC) ........................................................................... 113 7.2.4.1 Colorectal Cancer (CRC): Epidemiology ........................................................ 113 7.2.5Breast Cancer ............................................................................................ 114 7.2.5.1 Breast Cancer: Epidemiology ......................................................................... 114 7.2.6Urothelial Carcinoma ................................................................................ 115 7.2.6.1 Urothelial Carcinoma: Epidemiology ............................................................... 115 7.3 Germany ......................................................................................................... 116 7.3.1Non-Small Cell Lung Cancer (NSCLC) ..................................................... 117 7.3.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology .................................... 117 7.3.2Melanoma ................................................................................................... 118 7.3.2.1 Melanoma: Epidemiology ............................................................................... 118 7.3.3Hepatocellular Carcinoma (HCC) ............................................................. 119 7.3.3.1 Hepatocellular Carcinoma (HCC): Epidemiology ............................................ 119 7.3.4Colorectal Cancer (CRC) ........................................................................... 120 7.3.4.1 Colorectal Cancer (CRC): Epidemiology ........................................................ 120 7.3.5Breast Cancer ............................................................................................ 121 7.3.5.1 Breast Cancer: Epidemiology ......................................................................... 121 7.3.6Urothelial Carcinoma ................................................................................ 122 7.3.6.1 Urothelial Carcinoma: Epidemiology ............................................................... 122 7.4 France ............................................................................................................. 123 7.4.1Non-Small Cell Lung Cancer (NSCLC) ..................................................... 124 GLOBAL PD-1/PDL-1 INHIBITOR MARKET 7.4.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology .................................... 124 7.4.2Melanoma ................................................................................................... 125 7.4.2.1 Melanoma: Epidemiology ............................................................................... 125 7.4.3Hepatocellular Carcinoma (HCC) ............................................................. 126 7.4.3.1 Hepatocellular Carcinoma (HCC): Epidemiology ............................................ 126 7.4.4Colorectal Cancer (CRC) ........................................................................... 127 7.4.4.1 Colorectal Cancer (CRC): Epidemiology ........................................................ 127 7.4.5Breast Cancer ............................................................................................ 128 6 All rights reserved at BIS Research Inc.

  7. 7.4.5.1 Breast Cancer: Epidemiology ......................................................................... 128 7.4.6Urothelial Carcinoma ................................................................................ 129 7.4.6.1 Urothelial Carcinoma: Epidemiology ............................................................... 129 7.5 Italy ................................................................................................................. 130 7.5.1Non-Small Cell Lung Cancer (NSCLC) ..................................................... 131 7.5.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology .................................... 131 7.5.2Melanoma ................................................................................................... 132 7.5.2.1 Melanoma: Epidemiology ............................................................................... 132 7.5.3Hepatocellular Carcinoma (HCC) ............................................................. 133 7.5.3.1 Hepatocellular Carcinoma (HCC): Epidemiology ............................................ 133 7.5.4Colorectal Cancer (CRC) ........................................................................... 134 7.5.4.1 Colorectal Cancer (CRC): Epidemiology ........................................................ 134 7.5.5Breast Cancer ............................................................................................ 135 7.5.5.1 Breast Cancer: Epidemiology ......................................................................... 135 7.5.6Urothelial Carcinoma ................................................................................ 136 7.5.6.1 Urothelial Carcinoma: Epidemiology ............................................................... 136 7.6 Spain ............................................................................................................... 137 7.6.1Non-Small Cell Lung Cancer (NSCLC) ..................................................... 138 7.6.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology .................................... 138 7.6.2Melanoma ................................................................................................... 139 7.6.2.1 Melanoma: Epidemiology ............................................................................... 139 7.6.3Hepatocellular Carcinoma (HCC) ............................................................. 140 GLOBAL PD-1/PDL-1 INHIBITOR MARKET 7.6.3.1 Hepatocellular Carcinoma (HCC): Epidemiology ............................................ 140 7.6.4Colorectal Cancer (CRC) ........................................................................... 141 7.6.4.1 Colorectal Cancer (CRC): Epidemiology ........................................................ 141 7.6.5Breast Cancer ............................................................................................ 142 7.6.5.1 Breast Cancer: Epidemiology ......................................................................... 142 7.6.6Urothelial Carcinoma ................................................................................ 143 7.6.6.1 Urothelial Carcinoma: Epidemiology ............................................................... 143 7.7 Japan .............................................................................................................. 145 7 All rights reserved at BIS Research Inc.

  8. 7.7.1Non-Small Cell Lung Cancer (NSCLC) ..................................................... 146 7.7.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology .................................... 146 7.7.2Melanoma ................................................................................................... 147 7.7.2.1 Melanoma: Epidemiology ............................................................................... 147 7.7.3Hepatocellular Carcinoma (HCC) ............................................................. 148 7.7.3.1 Hepatocellular Carcinoma (HCC): Epidemiology ............................................ 148 7.7.4Colorectal Cancer (CRC) ........................................................................... 149 7.7.4.1 Colorectal Cancer (CRC): Epidemiology ........................................................ 149 7.7.5Breast Cancer ............................................................................................ 150 7.7.5.1 Breast Cancer: Epidemiology ......................................................................... 150 7.7.6Urothelial Carcinoma ................................................................................ 151 7.7.6.1 Urothelial Carcinoma: Epidemiology ............................................................... 151 8.Markets - Competitive Benchmarking & Company Profiles ....... 152 8.1 GlaxoSmithKline plc ...................................................................................... 153 8.1.1Company Overview ................................................................................... 153 8.1.2Role of GlaxoSmithKline plc in Global PD-1/PDL-1 Inhibitor Market .... 153 8.1.3Product Portfolio ....................................................................................... 154 8.1.4Key Competitors of the Company ............................................................ 154 8.1.5Financials ................................................................................................... 155 8.1.6Key Insights About Financial Health of the Company ........................... 157 8.1.7Business Strategies .................................................................................. 157 8.1.7.1 Product Developments ................................................................................... 157 GLOBAL PD-1/PDL-1 INHIBITOR MARKET 8.1.8Corporate Strategies ................................................................................. 158 8.1.8.1 Partnership and Collaboration ........................................................................ 158 8.1.9Analyst’s Perspective ............................................................................... 159 8.2 Bristol-Myers Squibb Company ................................................................... 160 8.2.1Company Overview ................................................................................... 160 8.2.2Role of Bristol-Myers Squibb Company in Global PD-1/PDL-1 Inhibitor Market.......................................................................................... 160 8.2.3Product Portfolio ....................................................................................... 161 8 All rights reserved at BIS Research Inc.

  9. 8.2.4Key Competitors of the Company ............................................................ 161 8.2.5Financials ................................................................................................... 162 8.2.6Key Insights About Financial Health of the Company ........................... 163 8.2.7Business Strategies .................................................................................. 164 8.2.7.1 Product Developments ................................................................................... 164 8.2.8Corporate Strategies ................................................................................. 168 8.2.8.1 Merger and Acquisitions ................................................................................. 168 8.2.9Analyst’s Perspective ............................................................................... 170 8.3 Arcus Biosciences, Inc.................................................................................. 171 8.3.1Company Overview ................................................................................... 171 8.3.2Role of Arcus Biosciences, Inc. in Global PD 1/PDL-1 inhibitor Market ......................................................................................................... 171 8.3.3Product Portfolio ....................................................................................... 172 8.3.4Key Competitors of the Company ............................................................ 172 8.3.5Financials ................................................................................................... 173 8.3.6Key Insights About Financial Health of the Company ........................... 174 8.3.7Business Strategies .................................................................................. 174 8.3.7.1 Product Developments ................................................................................... 174 8.3.8Corporate Strategies ................................................................................. 175 8.3.8.1 Partnerships and Collaboration ...................................................................... 175 8.3.9Analyst’s Perspective ............................................................................... 176 8.4 Agenus Inc. .................................................................................................... 177 GLOBAL PD-1/PDL-1 INHIBITOR MARKET 8.4.1Company Overview ................................................................................... 177 8.4.2Role of Agenus Inc. in Global PD 1/PDL-1 Inhibitor Market ................... 177 8.4.3Product Portfolio ....................................................................................... 177 8.4.4Financials ................................................................................................... 178 8.4.5Key Insights About Financial Health of the Company ........................... 179 8.4.6Business Strategies .................................................................................. 179 8.4.6.1 Product Developments ................................................................................... 179 8.4.7Corporate Strategies ................................................................................. 181 9 All rights reserved at BIS Research Inc.

  10. 8.4.7.1 Partnerships and Collaboration ...................................................................... 181 8.4.8Analyst’s Perspective ............................................................................... 182 8.5 F. Hoffmann-La Roche Ltd ............................................................................ 183 8.5.1Company Overview ................................................................................... 183 8.5.2Role of F. Hoffmann-La Roche Ltd in Global PD 1/PDL-1 inhibitor Market ......................................................................................................... 183 8.5.3Product Portfolio ....................................................................................... 184 8.5.4Key Competitors of the Company ............................................................ 184 8.5.5Financials ................................................................................................... 185 8.5.6Key Insights About Financial Health of the Company ........................... 186 8.5.7Business Strategies .................................................................................. 187 8.5.7.1 Product Developments ................................................................................... 187 8.5.8Corporate Strategies ................................................................................. 189 8.5.8.1 Partnership and Collaboration ........................................................................ 189 8.5.9Analyst’s Perspective ............................................................................... 190 8.6 Astra Zeneca PLC .......................................................................................... 191 8.6.1Company Overview ................................................................................... 191 8.6.2Role of Astra Zeneca PLC in Global PD 1/PDL-1 inhibitor Market ........ 191 8.6.3Product Portfolio ....................................................................................... 192 8.6.4Key Competitors of the Company ............................................................ 192 8.6.5Financials ................................................................................................... 193 8.6.6Key Insights About Financial Health of the Company ........................... 194 GLOBAL PD-1/PDL-1 INHIBITOR MARKET 8.6.7Business Strategies .................................................................................. 195 8.6.7.1 Product Developments ................................................................................... 195 8.6.8Corporate Strategies ................................................................................. 196 8.6.8.1 Partnership and Collaboration ........................................................................ 196 8.6.9Analyst’s Insight ........................................................................................ 196 8.7 Beigene Ltd. ................................................................................................... 197 8.7.1Company Overview ................................................................................... 197 8.7.2Role of Beigene Ltd. in Global PD 1/PDL-1 inhibitor Market.................. 197 10 All rights reserved at BIS Research Inc.

  11. 8.7.3Product Portfolio ....................................................................................... 198 8.7.4Key Competitors of the Company ............................................................ 199 8.7.5Financials ................................................................................................... 199 8.7.6Key Insights About Financial Health of the Company ........................... 200 8.7.7Business Strategies .................................................................................. 200 8.7.7.1 Product Developments ................................................................................... 200 8.7.8Corporate Strategies ................................................................................. 204 8.7.8.1 Partnership and Collaboration ........................................................................ 204 8.7.9Analyst’s Perspective ............................................................................... 205 8.8 Shanghai Junshi Bioscience Co. Ltd. .......................................................... 206 8.8.1Company Overview ................................................................................... 206 8.8.2Role of Shanghai Junshi Bioscience Co., Ltd. in Global PD 1/PDL-1 inhibitor Market.......................................................................................... 206 8.8.3Product Portfolio ....................................................................................... 207 8.8.4Key Competitors of the Company ............................................................ 207 8.8.5Financials ................................................................................................... 208 8.8.6Key Insights About Financial Health of the Company ........................... 208 8.8.7Business Strategies .................................................................................. 209 8.8.7.1 Product Developments ................................................................................... 209 8.8.8Corporate Strategies ................................................................................. 211 8.8.8.1 Partnership and Collaboration ........................................................................ 211 8.8.9Analyst’s Perspective ............................................................................... 212 GLOBAL PD-1/PDL-1 INHIBITOR MARKET 8.9 Shanghai Henlius Biotech, Inc. .................................................................... 213 8.9.1Company Overview ................................................................................... 213 8.9.2Role of Shanghai Henlius Biotech, Inc. in Global PD 1/PDL-1 inhibitor Market.......................................................................................... 213 8.9.3Product Portfolio ....................................................................................... 214 8.9.4Key Competitors of the Company ............................................................ 214 8.9.5Financials ................................................................................................... 215 8.9.6Key Insights About Financial Health of the Company ........................... 215 11 All rights reserved at BIS Research Inc.

  12. 8.9.7Business Strategies .................................................................................. 216 8.9.7.1 Product Developments ................................................................................... 216 8.9.8Corporate Strategies ................................................................................. 218 8.9.8.1 Partnership and Collaboration ........................................................................ 218 8.9.9Analyst’s Perspective ............................................................................... 219 8.10Jiangsu HengRui Medicine Co., Ltd. ............................................................ 220 8.10.1Company Overview ................................................................................... 220 8.10.2Role of Jiangsu HengRui Medicine Co., Ltd. in Global PD 1/PDL-1 Inhibitor Market.......................................................................................... 220 8.10.3Product Portfolio ....................................................................................... 221 8.10.4Key Competitors of the Company ............................................................ 221 8.10.5Financials ................................................................................................... 222 8.10.6Key Insights About Financial Health of the Company ........................... 222 8.10.7Business Strategies .................................................................................. 223 8.10.7.1 Product Developments ................................................................................... 223 8.10.8Corporate Strategies ................................................................................. 224 8.10.8.1 Partnership and Collaboration ........................................................................ 224 8.10.9Analyst’s Perspective ............................................................................... 224 8.11Lee's Pharmaceutical Limited....................................................................... 225 8.11.1Company Overview ................................................................................... 225 8.11.2Role of Lee's Pharmaceutical Limited in Global PD 1/PDL-1 inhibitor Market ......................................................................................................... 225 GLOBAL PD-1/PDL-1 INHIBITOR MARKET 8.11.3Product Portfolio ....................................................................................... 226 8.11.4Key Competitors of the Company ............................................................ 226 8.11.5Financials ................................................................................................... 227 8.11.6Key Insights About Financial Health of the Company ........................... 227 8.11.7Business Strategies .................................................................................. 228 8.11.7.1 Product Developments ................................................................................... 228 8.11.8Analyst’s Perspective ............................................................................... 228 8.12Incyte Corporation ......................................................................................... 229 12 All rights reserved at BIS Research Inc.

  13. 8.12.1Company Overview ................................................................................... 229 8.12.2Role of Incyte Corporation in Global PD-1/PDL-1 inhibitors Market ..... 229 8.12.3Product Portfolio ....................................................................................... 230 8.12.4Key Competitors of the Company ............................................................ 230 8.12.5Financials ................................................................................................... 231 8.12.6Key Insights About Financial Health of the Company ........................... 231 8.12.7Business Strategies .................................................................................. 232 8.12.7.1 Product Developments ................................................................................... 232 8.12.8Corporate Strategies ................................................................................. 233 8.12.8.1 Collaboration and Agreement ......................................................................... 233 8.12.9Analyst’s Perspective ............................................................................... 233 8.13Biocad ............................................................................................................. 234 8.13.1Company Overview ................................................................................... 234 8.13.2Role of Biocad in Global PD-1/PDL-1 Inhibitors Market ......................... 234 8.13.3Product Portfolio ....................................................................................... 235 8.13.4Key Competitors of the Company ............................................................ 235 8.13.5Business Strategies .................................................................................. 235 8.13.5.1 Product Developments ................................................................................... 235 8.13.6Corporate Strategies ................................................................................. 236 8.13.6.1 Partnership and Collaboration ........................................................................ 236 8.13.7Analyst’s Perspective ............................................................................... 236 8.14CStone Pharmaceuticals ............................................................................... 237 GLOBAL PD-1/PDL-1 INHIBITOR MARKET 8.14.1Company Overview ................................................................................... 237 8.14.2Role of CStone Pharmaceuticals in Global PD-1/PDL-1 Inhibitors Market ......................................................................................................... 237 8.14.3Product Portfolio ....................................................................................... 238 8.14.4Key Competitors of the Company ............................................................ 238 8.14.5Financials ................................................................................................... 239 8.14.6Key Insights About Financial Health of the Company ........................... 240 8.14.7Business Strategies .................................................................................. 241 13 All rights reserved at BIS Research Inc.

  14. 8.14.7.1 Product Developments ................................................................................... 241 8.14.8Corporate Strategies ................................................................................. 242 8.14.8.1 Partnership and Collaboration ........................................................................ 242 8.14.9Analyst’s Perspective ............................................................................... 242 9.BIS Research Recommendations ............................................ 243 9.1 Current Market Scenario ............................................................................... 243 9.2 Future Scenario ............................................................................................. 243 9.3 Key Success Factors and Challenges ......................................................... 243 9.3.1Success Factors ........................................................................................ 243 9.3.2Key Challenges .......................................................................................... 244 GLOBAL PD-1/PDL-1 INHIBITOR MARKET 14 All rights reserved at BIS Research Inc.

  15. List of Figures Figure 1: PD-1/PDL-1 Inhibitor Market Share (by Sales), $Million, 2021 Figure 2: Number of Eligible Patients Specific to Indication for 2022 Figure 3: Global PD-1/PDL-1 Inhibitor Market Segmentation Figure 4: Global PD-1/PDL-1 Inhibitor Market Methodology Figure 5: Primary Research Methodology Figure 6: Historic Development of PD-1/PDL-1 Inhibitors Figure 7: Role of PD-1/PDL-1 in Tumor Protection Figure 8: Key Market Players (by Sales), $Million, 2021 Figure 9: Number of Strategic Activities Figure 10: Regional Distribution of Companies Figure 11: Non-Small Cell Lung Cancer (NSCLC) Disease Pathophysiology Figure 12: Melanoma Disease Pathophysiology Figure 13: Melanoma: Treatment Options Figure 14: Hepatocellular Carcinoma (HCC): Disease Pathophysiology Figure 15: Hepatocellular Carcinoma (HCC) Treatment Figure 16: Hepatocellular Carcinoma (HCC) Treatment Algorithm Figure 17: Chromosomal Instability (CIN) Pathway and Microsatellite Instability (MSI) Pathway Figure 18: Serrated Pathway Figure 19: Colorectal Cancer (CRC): Treatment Algorithm Figure 20: Breast Cancer: Disease Pathophysiology Figure 21: Breast Cancer: Treatment Figure 22: Urothelial Carcinoma: Disease Pathophysiology GLOBAL PD-1/PDL-1 INHIBITOR MARKET Figure 23: Urothelial Carcinoma Treatment Types Figure 24: Urothelial Carcinoma Treatment Algorithm Figure 25: Number of PD-1/PDL-1 Inhibitor Clinical Trials Figure 26: Number of Clinical Trials by Drug Class Figure 27: PD-1/PDL-1 Inhibitor by Therapy (Monotherapy/Combination) Type Figure 28: PD-1/PDL-1 Inhibitors with Added Entity Figure 29: U.S. Eligible Population for PD-1/PDL-1 Inhibitor Treatment Figure 30: U.S. Eligible Patient Population for Melanoma, 2022-2032 Figure 31: U.S. Eligible Patient Population for Breast Cancer, 2022-2032 15 All rights reserved at BIS Research Inc.

  16. Figure 32: U.S. Eligible Patient Population for Colorectal Cancer, 2022-2032 Figure 33: U.S. Eligible Patient Population for NSCLC, 2022-2032 Figure 34: U.S. Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032 Figure 35: U.S. Eligible Patient Population for Urothelial Carcinoma, 2022-2032 Figure 36: U.K. Eligible Population for PD-1/PDL-1 Inhibitor Treatment Figure 37: U.K. Eligible Patient Population for NSCLC, 2022-2032 Figure 38: U.K. Eligible Patient Population for Melanoma, 2022-2032 Figure 39: U.K. Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032 Figure 40: U.K. Eligible Patient Population for Colorectal Cancer, 2022-2032 Figure 41: U.K. Eligible Patient Population for Breast Cancer, 2022-2032 Figure 42: U.K. Eligible Patient Population for Urothelial Carcinoma, 2022-2032 Figure 43: Germany Eligible Population for PD-1/PDL-1 Inhibitor Treatment Figure 44: Germany: Eligible Patient Population for NSCLC, 2022-2032 Figure 45: Germany: Eligible Patient Population for Melanoma, 2022-2032 Figure 46: Germany: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032 Figure 47: Germany: Eligible Patient Population for Colorectal Cancer, 2022-2032 Figure 48: Germany: Eligible Patient Population for Breast Cancer, 2022-2032 Figure 49: Germany: Eligible Patient Population for Urothelial Carcinoma, 2022-2032 Figure 50: France Eligible Population for PD-1/PDL-1 Inhibitor Treatment Figure 51: France: Eligible Patient Population for NSCLC, 2022-2032 Figure 52: France: Eligible Patient Population for Melanoma, 2022-2032 Figure 53: France: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032 Figure 54: France: Eligible Patient Population for Colorectal Cancer, 2022-2032 Figure 55: France: Eligible Patient Population for Breast Cancer, 2022-2032 GLOBAL PD-1/PDL-1 INHIBITOR MARKET Figure 56: France: Eligible Patient Population for Urothelial Carcinoma, 2022-2032 Figure 57: Italy Eligible Population for PD-1/PDL-1 Inhibitor Treatment Figure 58: Italy: Eligible Patient Population for NSCLC, 2022-2032 Figure 59: Italy: Eligible Patient Population for Melanoma, 2022-2032 Figure 60: Italy: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032 Figure 61: Italy: Eligible Patient Population for Colorectal Cancer, 2022-2032 Figure 62: Italy: Eligible Patient Population for Breast Cancer, 2022-2032 Figure 63: Italy: Eligible Patient Population for Urothelial Carcinoma, 2022-2032 Figure 64: Spain Eligible Population for PD-1/PDL-1 Inhibitor Treatment 16 All rights reserved at BIS Research Inc.

  17. Figure 65: Spain: Eligible Patient Population for NSCLC, 2022-2032 Figure 66: Spain: Eligible Patient Population for Melanoma, 2022-2032 Figure 67: Spain: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032 Figure 68: Spain: Eligible Patient Population for Colorectal Cancer, 2022-2032 Figure 69: Spain: Eligible Patient Population for Breast Cancer, 2022-2032 Figure 70: Spain: Eligible Patient Population for Urothelial Carcinoma, 2022-2032 Figure 71: Japan Eligible Population for PD-1/PDL-1 Inhibitor Treatment Figure 72: Japan: Eligible Patient Population for NSCLC, 2022-2032 Figure 73: Japan: Eligible Patient Population for Melanoma, 2022-2032 Figure 74: Japan: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032 Figure 75: Japan: Eligible Patient Population for Colorectal Cancer, 2022-2032 Figure 76: Japan: Eligible Patient Population for Breast Cancer, 2022-2032 Figure 77: Japan: Eligible Patient Population for Urothelial Carcinoma, 2022-2032 Figure 78: GlaxoSmithKline plc: Product Portfolio Figure 79: GlaxoSmithKline plc: Overall Financials, $Million, 2019-2021 Figure 80: GlaxoSmithKline plc: Net Revenue (by Segment), $Million, 2019-2021 Figure 81: GlaxoSmithKline plc: Net Revenue (by Region), $Million, 2019-2021 Figure 82: GlaxoSmithKline plc: R&D Expenditure, $Million, 2019-2021 Figure 83: Bristol-Myers Squibb Company: Product Portfolio Figure 84: Bristol-Myers Squibb Company: Overall Financials, $Million, 2019-2021 Figure 85: Bristol-Myers Squibb Company: Net Revenue (by Region), $Million, 2019-2021 Figure 86: Bristol-Myers Squibb Company: R&D Expenditure, $Million, 2019-2021 Figure 87: Arcus Biosciences, Inc.: Product Portfolio Figure 88: Arcus Biosciences, Inc.: Overall Financials, $Million, 2019-2021 GLOBAL PD-1/PDL-1 INHIBITOR MARKET Figure 89: Arcus Biosciences, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 90: Agenus Inc.: Product Portfolio Figure 91: Agenus Inc.: Overall Financials, $Million, 2019-2021 Figure 92: Agenus Inc.: Net Revenue (by Region), $Million, 2019-2021 Figure 93: Agenus Inc.: R&D Expenditure, $Million, 2019-2021 Figure 94: F. Hoffmann-La Roche Ltd: Product Portfolio Figure 95: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021 Figure 96: F. Hoffmann-La Roche Ltd: Net Revenue (by Segment), $Million, 2019-2021 Figure 97: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021 17 All rights reserved at BIS Research Inc.

  18. Figure 98: Astra Zeneca PLC: Product Portfolio Figure 99: Astra Zeneca PLC: Overall Financials, $Million, 2019-2021 Figure 100: Astra Zeneca PLC: Net Revenue (by Region), $Million, 2019-2021 Figure 101: Astra Zeneca PLC: R&D Expenditure, $Million, 2019-2021 Figure 102: Beigene Ltd.: Product Portfolio Figure 103: Beigene Ltd.: Overall Financials, $Million, 2019-2021 Figure 104: Beigene Ltd.: R&D Expenditure, $Million, 2019-2021 Figure 105: Shanghai Junshi Bioscience Co., Ltd.: Product Portfolio Figure 106: Shanghai Junshi Bioscience Co., Ltd.: Overall Financials, $Million, 2019-2021 Figure 107: Shanghai Junshi Bioscience Co., Ltd.: R&D Expenditure, $Million, 2019-2021 Figure 108: Shanghai Henlius Biotech, Inc.: Product Portfolio Figure 109: Shanghai Henlius Biotech, Inc.: Overall Financials, $Million, 2019-2021 Figure 110: Shanghai Henlius Biotech, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 111: Jiangsu HengRui Medicine Co., Ltd.: Product Portfolio Figure 112: Jiangsu HengRui Medicine Co., Ltd.: Overall Financials, $Million, 2019-2021 Figure 113: Jiangsu HengRui Medicine Co., Ltd.: R&D Expenditure, $Million, 2019-2021 Figure 114: Lee's Pharmaceutical Limited: Product Portfolio Figure 115: Lee's Pharmaceutical Limited: Overall Financials, $Million, 2019-2021 Figure 116: Lee's Pharmaceutical Limited: R&D Expenditure, $Million, 2019-2021 Figure 117: Incyte Corporation: Product Portfolio Figure 118: Incyte Corporation: Overall Financials, $Million, 2019-2021 Figure 119: Incyte Corporation R&D Expenditure, $Million, 2019-2021 Figure 120: Biocad: Product Portfolio Figure 121: CStone Pharmaceuticals: Product Portfolio GLOBAL PD-1/PDL-1 INHIBITOR MARKET Figure 122: CStone Pharmaceuticals: Overall Financials, $Million, 2019-2021 Figure 123: CStone Pharmaceuticals: Revenue (by Region), $Million, 2019-2021 Figure 124: CStone Pharmaceuticals: R&D Expenditure, $Million, 2019-2021 18 All rights reserved at BIS Research Inc.

  19. List of Tables Table 1: Approved PD-1/PDL-1 Inhibitors Table 2: Snapshot: Approved PD-1/PDL-1 Inhibitors Table 3: Companies by Region Table 4: Number of Indication Added Since Launch Table 5: Combination Regimen with PD-1/PDL-1 Inhibitors Table 6: Non-Small Cell Lung Cancer (NSCLC): Stage Specific Treatment Options Table 7: Stage-Wise Colorectal Cancer (CRC) Treatment Table 8: Systemic Therapy for Distant Recurrence Cases of Colorectal Cancer (CRC) Table 9: PD-1/PDL-1 Inhibitor by Route of Administration (RoA) Table 10: Combination Regimes by Development Stage Table 11: Leading PD-1/PDL-1 Inhibitors and Indications in Combination Therapy Table 12: Leading PD-1/PDL-1 Inhibitors as Monotherapy and Target Indication Table 13: U.S. Incidence for Cancer Indications, 2022-2032 Table 14: U.S. Prevalence for Cancer Indications, 2022-2032 Table 15: U.K. Incidence for Cancer Indications, 2022-2032 Table 16: U.K. Prevalence for Cancer Indications, 2022-2032 Table 17: Germany Incidence for Cancer Indications, 2022-2032 Table 18: Germany Prevalence for Cancer Indications, 2022-2032 Table 19: France Incidence for Cancer Indications, 2022-2032 Table 20: France Prevalence for Cancer Indications, 2022-2032 Table 21: Italy Incidence for Cancer Indications, 2022-2032 Table 22: Italy Prevalence for Cancer Indications, 2022-2032 GLOBAL PD-1/PDL-1 INHIBITOR MARKET Table 23: Spain Incidence for Cancer Indications, 2022-2032 Table 24: Spain Prevalence for Cancer Indications, 2022-2032 Table 25: Japan Incidence for Cancer Indications, 2022-2032 Table 26: Japan Prevalence for Cancer Indications, 2022-2032 Table 27: GlaxoSmithKline plc: Key Competitors Table 28: Product Development Table 29: Partnership and Collaboration Table 30: Potential Registrational Study Readouts Anticipated Through 2023/2024 Table 31: Bristol-Myers Squibb Company: Key Competitors 19 All rights reserved at BIS Research Inc.

  20. Table 32: Product Developments Table 33: Merger and Acquisitions Table 34: Arcus Biosciences, Inc.: Key Competitors Table 35: Product Developments Table 36: Partnerships and Collaboration Table 37: Product Developments Table 38: Partnerships and Collaboration Table 39: F. Hoffmann-La Roche Ltd: Key Competitors Table 40: Product Developments Table 41: Partnership and Collaboration Table 42: Astra Zeneca PLC: Key Competitors Table 43: Product Developments Table 44: Partnership and Collaboration Table 45: Beigene Ltd.: Key Competitors Table 46: Product Developments Table 47: Partnership and Collaboration Table 48: Shanghai Junshi Bioscience Co., Ltd.: Key Competitors Table 49: Product Developments Table 50: Partnership and Collaboration Table 51: Shanghai Henlius Biotech, Inc.: Key Competitors Table 52: Product Developments Table 53: Partnership and Collaboration Table 54: Jiangsu HengRui Medicine Co., Ltd.: Key Competitors Table 55: Product Developments GLOBAL PD-1/PDL-1 INHIBITOR MARKET Table 56: Partnership and Collaboration Table 57: Lee's Pharmaceutical Limited: Key Competitors Table 58: Product Developments Table 59: Product Developments Table 60: Collaboration and Agreement Table 61: Product Developments Table 62: Partnership and Collaboration Table 63: Product Developments Table 64: Partnership and Collaboration 20 All rights reserved at BIS Research Inc.

  21. BIS Research Offerings: We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. We have a vision to be a leading and preferred knowledge partner for corporates and institutions worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other innovative solutions. Know More Know More Know More GLOBAL PD-1/PDL-1 INHIBITOR MARKET Know More 21 All rights reserved at BIS Research Inc.

  22. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties and contingencies For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 GLOBAL PD-1/PDL-1 INHIBITOR MARKET 22 All rights reserved at BIS Research Inc.

  23. BIS RESEARCH INC. GLOBAL PD-1/PDL-1 INHIBITOR MARKET 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135 Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 www.bisresearch.com 23 All rights reserved at BIS Research Inc.

More Related